Humira (adalimumab) has finally lost its position as the bestselling drug in the world, but it took a pandemic to finally unseat it from the number one spot.
Despite sales of the anti-TNF blockbuster continuing to grow throughout the year, AbbVie Inc.’s product was overtaken by Pfizer Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?